{"id":7496,"date":"2011-04-04T12:16:55","date_gmt":"2011-04-04T16:16:55","guid":{"rendered":"http:\/\/blogs.nejm.org\/cardioexchange\/?p=7496"},"modified":"2011-07-19T17:44:28","modified_gmt":"2011-07-19T21:44:28","slug":"precombat-explores-pci-versus-cabg-for-left-main-disease","status":"publish","type":"post","link":"https:\/\/blogs.nejm.org\/cardioexchange\/2011\/04\/04\/precombat-explores-pci-versus-cabg-for-left-main-disease\/","title":{"rendered":"PRECOMBAT Explores PCI Versus CABG for Left Main Disease"},"content":{"rendered":"<p>In the PRECOMBAT trial, Korean investigators randomized 600 patients with unprotected left main disease to either PCI with a sirolimus-eluting stent or CABG. The results were presented at the ACC and <a href=\"http:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa1100452?query=featured_home\">published simultaneously in the <em>New England Journal of Medicine<\/em>.<\/a><\/p>\n<p>At 1 year, the incidence of the primary composite endpoint &#8211; death from any cause, MI, stroke, or ischemia-driven target-vessel revascularization &#8211; was 8.7% (26 patients) in the PCI group versus 6.7% (20 patients) in the CABG group, for an absolute risk reduction of 2% (95% CI -1.6 &#8211; 5.6, p=0.01 for noninferiority). At 2 years, the incidence was 12.2%\u00a0 for PCI versus 8.1% for CABG (HR 1.50, 95% CI 0.90 -2.52, p=0.12).<\/p>\n<p>The authors conclude that although the trial &#8220;met the prespecified criterion for noninferiority,&#8221; their results &#8220;cannot be considered to be clinically directive&#8221; because &#8220;the power of the trial was lower than anticipated and because the noninferiority margin was wide.&#8221;<\/p>\n<p><em>For more of our ACC.11 coverage of late-breaking clinical trials,   interviews with the authors of the most important research, and blogs   from our fellows on the most interesting presentations at the meeting,   check out our <a href=\"..\/acc-11-cardioexchange-coverage-roundup\/\">Coverage Roundup<\/a>.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>In the PRECOMBAT trial, Korean investigators randomized 600 patients with unprotected left main disease to either PCI with a sirolimus-eluting stent or CABG. The results were presented at the ACC and published simultaneously in the New England Journal of Medicine. At 1 year, the incidence of the primary composite endpoint &#8211; death from any cause, [&hellip;]<\/p>\n","protected":false},"author":196,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[20,9],"tags":[781],"class_list":["post-7496","post","type-post","status-publish","format-standard","hentry","category-cardiac-surgery","category-interventional-cardiology","tag-left-main-disease"],"_links":{"self":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/7496","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/users\/196"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/comments?post=7496"}],"version-history":[{"count":0,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/7496\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/media?parent=7496"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/categories?post=7496"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/tags?post=7496"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}